Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office

Jupiter, FL, Jan. 05, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s DuraGraft related patent application entitled “Solutions for Increasing the Stability and Shelf Life of an Organ and Tissue Preservation Solution.” The allowed patent application No. 14/906,582 covers an organ and tissue preservation kit containing shelf-life stable solutions used for vascular graft and tissue protection and preservation during coronary artery bypass surgery (CABG) and other vascular surgeries.

The allowed patent protects Marizyme’s flagship commercial product DuraGraft®, a first-in-class CE marked intra-operative graft storage solution that protects vascular grafts against ischemic injury during bypass surgeries and reduces the incidence of complications associated with vein graft failure, leading to improved clinical outcomes. DuraGraft®, the only product approved for graft protection and preservation during bypass and other vascular surgeries, is currently approved and marketed in Europe and several other leading global healthcare markets. Marizyme is actively seeking United States FDA approval for DuraGraft.

The notification of allowance from the USPTO further strengthens Marizyme’s patent estate for DuraGraft which already includes granted or allowed patents in Europe, Australia, Argentina, Brazil, China, South Africa, Mexico, and several Asian countries.  “Allowance of this DuraGraft patent application in the United States represents a significant milestone for us,” stated David Barthel, Marizyme’s CEO, and “protects our commercial opportunities for DuraGraft in the US.”

About Marizyme:

Marizyme is life sciences company, based in Jupiter, FL that is engaged in the research, development and commercialization of technologies and products to prevent, treat and diagnose diseases with unmet clinical need. The Company’s flagship product, DuraGraft® is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on developing and commercializing consumer focused handheld point-of-care diagnostic devices that connect to patients’ smartphones and digital continued care platforms. Additionally, the Company is developing and marketing products based on its clinically tested and proprietary protease based therapeutic Krillase® platform. Krillase is not approved for use in the U.S.  For more information about Marizyme, visit www.marizyme.com

Forward Looking Statements

This press release contains statements that do not relate to historical facts but are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  These statements can generally (although not always) be identified by their use of terms and phrases such as anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense.  Forward-looking statements are neither historical facts nor assurances of future performance.  Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of our company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.  Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control, including the risks described in our annual and quarterly reports under the heading “Risk Factors” as filed with the SEC.  Actual results and financial condition may differ materially from those indicated in the forward-looking statements.  Therefore, you should not rely on any of these forward-looking statements.  Forward-looking statements in this press release speak only as of the date hereof.  Unless otherwise required by law, we undertake no obligation to publicly update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Bradley Richmond
9147148615
brichmond@marizyme.com